Flavoxate HCl tablets contain flavoxate hydrochloride, a synthetic urinary tract spasmolytic.
Flavoxate HCl tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate HCl tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections.
Clinical Trials Related to Flavoxate
Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy (TURP) [Completed]
The purpose of this study is to determine whether etoricoxib, flavoxate, both are effective
in the treatment postoperative pain after TURP.
The research hypothesis:
There is a difference in postoperative morphine consumption in the first 24 hours after
transurethral prostatectomy between patients who received etoricoxib or flavoxate or both
A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions [Completed]
The purpose of this study is to compare the relative bioavailability of Flavoxate
Hydrochloride tablets 100mg manufactured by Paddock Laboratories, Inc., with that of
UrispasŪ tablets 100mg by SmithKline Beecham Pharmaceuticals under fasting conditions.